Kobayashi et al. (2015) labeled an anti-mesothelin mAb (11–25 mAb) with 64-copper (64Cu) and demonstrated its high accumulation in mesothelin-expressing tumors compared to mesothelin-negative tumors as well as its potential to detect mesothelin-expressing pancreatic cancers by PET imaging (in vivo) [20]. This evidence concerns the gene MSLN and familial pancreatic carcinoma.